Association Between Hepatitis C Infection and Renal Cell Carcinoma
This study is currently recruiting participants.
Verified June 2011 by Henry Ford Health System
Sponsor:
Henry Ford Health System
Collaborator:
Schering-Plough
Information provided by:
Henry Ford Health System
ClinicalTrials.gov Identifier:
NCT01405183
First received: July 28, 2011
Last updated: August 12, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if there is an association between hepatitis C infection and kidney cancer. All patients who are diagnosed with kidney cancer and who will either have a biopsy or surgery will be offered to be tested for hepatitis C. The control group will be colon cancer patients. Both groups would be of recent diagnosis (6 months).
| Condition | Intervention |
|---|---|
|
Hepatitis C Renal Cell Carcinoma Colorectal Cancer |
Other: Hepatitis C testing |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Association Between Hepatitis C Infection and Renal Cell Carcinoma, a Case Control Study |
Resource links provided by NLM:
MedlinePlus related topics:
Cancer
Colorectal Cancer
Hepatitis
Hepatitis A
Hepatitis C
Kidney Cancer
Drug Information available for:
Hepatitis A Vaccines
U.S. FDA Resources
Further study details as provided by Henry Ford Health System:
Primary Outcome Measures:
- Prevalence of hepatitis C in renal cell carcinoma patients [ Time Frame: 2 years ] [ Designated as safety issue: No ]Determine the prevalence of hepatitis C infection in newly diagnosed renal cell carcinoma patients
Biospecimen Retention: Samples Without DNA
Hepatits C antibody Hepatitis C RNA quantitative Hepatitis C Genotype
| Estimated Enrollment: | 278 |
| Study Start Date: | January 2011 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Renal Cell Carcinoma patients
Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed
|
Other: Hepatitis C testing
Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
|
|
Colorectal cancer patients
Newly diagnosed (6 months) colon cancer patients
|
Other: Hepatitis C testing
Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Renal cell carcinoma patients will be identified from the urology clinic and from the hospital wards.
Colorectal cancer patient will be identifed from the hospital wards, pathology reports and gastroenterology endoscopy suits.
Criteria
Inclusion Criteria:
- Male and female patients 18 years or older in whom renal cell carcinoma is suspected and are scheduled for either biopsy or partial or total nephrectomy. Diagnosis within 6 months.
- Male and female patients 18 years or older in whom colorectal cancer has been diagnosed within the last 6 months
Exclusion Criteria:
- Patients who are unwilling to provide consent
- Patients who decline to complete a questionnaire
- Patient in who blood sample cannot be obtained
- Diagnosis of renal cell carcinoma or colon cancer greater than 6 months
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01405183
Locations
| United States, Michigan | |
| Henry Ford Hospital | Recruiting |
| Detroit, Michigan, United States, 48202 | |
| Contact: Humberto C Gonzalez, MD 313-916-2424 hgonzal1@hfhs.org | |
| Contact: Margaret French, RN 313-916-3369 mfrench1@hfhs.org | |
| Principal Investigator: Humberto C Gonzalez, MD | |
| Sub-Investigator: Stuart C Gordon, MD | |
| Sub-Investigator: Craig Rogers, MD | |
| Sub-Investigator: Lois Lamerato, PhD | |
Sponsors and Collaborators
Henry Ford Health System
Schering-Plough
Investigators
| Principal Investigator: | Humberto C Gonzalez, MD | Henry Ford Hospital |
| Study Chair: | Stuart C Gordon, MD | Henry Ford Hospital |
More Information
Publications:
| Responsible Party: | Humberto C. Gonzalez, MD, Gastroenterology Fellow |
| ClinicalTrials.gov Identifier: | NCT01405183 History of Changes |
| Other Study ID Numbers: | P08406 |
| Study First Received: | July 28, 2011 |
| Last Updated: | August 12, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Henry Ford Health System:
|
Hepatitis C Renal Cell Carcinoma Colorectal Cancer |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Renal Cell Colorectal Neoplasms Hepatitis Hepatitis A Hepatitis C Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases |
Urologic Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Liver Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections |
ClinicalTrials.gov processed this record on May 16, 2013